Classification of current anticancer immunotherapies
暂无分享,去创建一个
Axel Hoos | Patrizia Agostinis | Fernando Aranda | Jedd D. Wolchok | Angel Porgador | Pramod K. Srivastava | Daniel E. Speiser | Aled Clayton | Laurence Zitvogel | Klas Kärre | Hermann Wagner | Kenneth J. Pienta | Laura Bracci | Hans Schreiber | Eli Gilboa | Fabrizio Mattei | Jean-Yves Blay | Federica Cavallo | John M. Kirkwood | Jérôme Galon | Dirk Jäger | Gabriel A. Rabinovich | Enrico Lugli | Mark J. Smyth | Lorenzo Galluzzi | Guido Kroemer | Elizabeth A. Mittendorf | Jean-Pierre Abastado | Claire E. Lewis | Weiping Zou | Michael T. Lotze | Vincenzo Cerundolo | Wolf H. Fridman | Dmitry I. Gabrilovich | Sacha Gnjatic | S. H. van der Burg | Oliver Kepp | K. Pienta | G. Giaccone | J. Blay | D. Jäger | A. Palucka | E. Gilboa | M. Peter | B. Seliger | J. Wolchok | M. Dhodapkar | J. Kirkwood | L. Zitvogel | L. Galluzzi | O. Kepp | G. Kroemer | C. Melief | L. Coussens | G. Prendergast | R. Vile | G. Rabinovich | M. Colombo | E. Vacchelli | E. Tartour | C. Sautès-Fridman | J. Galon | W. Fridman | P. Agostinis | P. Srivastava | D. Speiser | M. Lotze | L. Senovilla | N. Rizvi | I. Melero | V. Cerundolo | D. Fearon | T. Whiteside | J. Abastado | J. Talmadge | E. Mittendorf | A. Clayton | C. Lewis | R. Kiessling | A. Porgador | E. Klein | R. Liblau | M. Smyth | S. Gnjatic | F. Ghiringhelli | H. Schreiber | H. Wagner | L. Bracci | H. Okada | Abhishek D Garg | W. Zou | L. Moretta | D. Gabrilovich | J. Weber | E. Lugli | B. Silva-Santos | F. Mattei | N. Restifo | R. Apte | H. Shiku | A. Hoos | P. Beckhove | P. Kalinski | F. Cavallo | B. J. Van den Eynde | A. Knuth | A. Buqué | N. Bloy | C. Castelli | J. Fucikova | R. Spíšek | M. Ayyoub | D. Mavilio | J. Mach | Giuseppe Giaccone | Philipp Beckhove | Ignacio Melero | K. Kärre | Hiroshi Shiku | Marcus E. Peter | François Ghiringhelli | Barbara Seliger | Lorenzo Moretta | Eric Tartour | Catherine Sautès-Fridman | Alexander Knuth | Nicholas P. Restifo | Mario P. Colombo | Theresa L. Whiteside | Hideho Okada | Roland Liblau | Fernando Aranda | Chiara Castelli | J. B. Pedro | E. Baracco | F. Castoldi | A. Caignard | Estaban Celis | A. Eggermont | A. Hosmalin | Adekunke Odunsi | Ron N. Apte | Bruno Silva-Santos | Anna Karolina Palucka | Pawel Kalinski | Maha Ayyoub | Jeffrey S. Weber | Rolf Kiessling | Domenico Mavilio | Douglas T. Fearon | James E. Talmadge | Naiyer Rizvi | Eva Klein | Erika Vacchelli | Madhav V. Dhodapkar | Anne Hosmalin | George C. Prendergast | Jean-Pierre Mach | Lisa Coussens | Jitka Fučíková | José-Manuel Bravo-San Pedro | Aitziber Buqué | Laura Senovilla | Elisa Elena Baracco | Norma Bloy | Francesca Castoldi | Anne Caignard | Estaban Celis | Alexander M. Eggermont | Abhishek Garg | Cornelis J. Melief | Adekunke Odunsi | Radek Spisek | Sjoerd H. Van Der Burg | Benoît J. Van Den Eynde | Richard Vile | E. E. Baracco | Erika Vacchelli
[1] G. Bepler,et al. Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer , 2006, Clinical Cancer Research.
[2] Craig Murdoch,et al. The role of myeloid cells in the promotion of tumour angiogenesis , 2008, Nature Reviews Cancer.
[3] Michael Platten,et al. Treatment of Autoimmune Neuroinflammation with a Synthetic Tryptophan Metabolite , 2005, Science.
[4] D. Ciocca,et al. Heat shock proteins (HSPs) based anti-cancer vaccines. , 2012, Current molecular medicine.
[5] B. Blazar,et al. Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth. , 2012, Cancer research.
[6] G. Linette,et al. Dendritic cell-based vaccines , 2013, Oncoimmunology.
[7] Drew A. Torigian,et al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer , 2013, Oncoimmunology.
[8] L. Zitvogel,et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity , 1995, Nature Medicine.
[9] D. Heymann,et al. Mifamurtide for the treatment of nonmetastatic osteosarcoma , 2011, Expert opinion on pharmacotherapy.
[10] E. Gilboa,et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. , 2005, The Journal of clinical investigation.
[11] J. Zucman‐Rossi,et al. Trial Watch: Monoclonal antibodies in cancer therapy , 2012, Oncoimmunology.
[12] A. Corti,et al. Won’t you come on in? How to favor lymphocyte infiltration in tumors , 2012, Oncoimmunology.
[13] Denise A. Martin,et al. West Nile Virus Recombinant DNA Vaccine Protects Mouse and Horse from Virus Challenge and Expresses In Vitro a Noninfectious Recombinant Antigen That Can Be Used in Enzyme-Linked Immunosorbent Assays , 2001, Journal of Virology.
[14] L. Zitvogel,et al. Trial watch , 2012, Oncoimmunology.
[15] M. Liang. Clinical development of oncolytic viruses in China. , 2012, Current pharmaceutical biotechnology.
[16] L. Coussens,et al. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. , 2014, Cancer cell.
[17] S. Karasawa,et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide , 2012, Leukemia.
[18] A. Palucka,et al. Dendritic cells as therapeutic vaccines against cancer , 2005, Nature Reviews Immunology.
[19] PD-1 inhibitor approved for melanoma. , 2014, Cancer discovery.
[20] D. Dabkara,et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma , 2008 .
[21] B. Quesnel,et al. Administration of alemtuzumab and G‐CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study , 2013, European journal of haematology.
[22] I. Fidler,et al. Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide. , 1987, Journal of immunology.
[23] J. Allison,et al. CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection , 2012, Oncoimmunology.
[24] R. Sauer,et al. Radiation combined with hyperthermia induces HSP70-dependent maturation of dendritic cells and release of pro-inflammatory cytokines by dendritic cells and macrophages. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[25] B. Chain,et al. Epitope spreading contributes to effective immunotherapy in metastatic melanoma patients. , 2011, Immunotherapy.
[26] C. Breitbach,et al. Going viral with cancer immunotherapy , 2014, Nature Reviews Cancer.
[27] J. Drach,et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Bethan Hughes. Antibody–drug conjugates for cancer: poised to deliver? , 2010, Nature Reviews Drug Discovery.
[29] S. Rosenberg,et al. CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma , 2012, Clinical Cancer Research.
[30] A. Adler,et al. Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation , 2013, Oncoimmunology.
[31] B. Baban,et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. , 2004, The Journal of clinical investigation.
[32] Cristina M. Tato,et al. SnapShot: Cytokines III , 2008, Cell.
[33] G. Trinchieri,et al. Murine Plasmacytoid Dendritic Cells Initiate the Immunosuppressive Pathway of Tryptophan Catabolism in Response to CD200 Receptor Engagement1 , 2004, The Journal of Immunology.
[34] P. Scherle,et al. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors , 2006, Nature Reviews Cancer.
[35] T. Salo,et al. Toll-like receptor 5 and the emerging role of bacteria in carcinogenesis , 2013, Oncoimmunology.
[36] C. Figdor,et al. Naturally circulating dendritic cells to vaccinate cancer patients , 2013, Oncoimmunology.
[37] Xiaopei Huang,et al. Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation. , 2012, Blood.
[38] L. Galluzzi,et al. Organelle-specific initiation of cell death , 2014, Nature Cell Biology.
[39] S. H. van der Burg,et al. CD8+ CTL Priming by Exact Peptide Epitopes in Incomplete Freund’s Adjuvant Induces a Vanishing CTL Response, whereas Long Peptides Induce Sustained CTL Reactivity1 , 2007, The Journal of Immunology.
[40] C. Goyvaerts,et al. Assessing T-cell responses in anticancer immunotherapy , 2013, Oncoimmunology.
[41] Trial Watch , 2014, Oncoimmunology.
[42] A. Gaggar,et al. The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.
[43] V. Fazio,et al. DNA Vaccines: Developing New Strategies against Cancer , 2010, Journal of biomedicine & biotechnology.
[44] W. Wels,et al. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity , 2013, Oncoimmunology.
[45] P. Ricciardi-Castagnoli,et al. The B Subunit of Shiga Toxin Fused to a Tumor Antigen Elicits CTL and Targets Dendritic Cells to Allow MHC Class I-Restricted Presentation of Peptides Derived from Exogenous Antigens1 , 2000, The Journal of Immunology.
[46] M. Sporn,et al. The tumour microenvironment as a target for chemoprevention , 2007, Nature Reviews Cancer.
[47] J. Wolchok,et al. Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells , 2013, Clinical Cancer Research.
[48] David L. Porter,et al. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.
[49] Cancer vaccines: Looking to the future. , 2013, Oncoimmunology.
[50] Bei Wang. Targeting dendritic cells in situ for breast cancer immunotherapy , 2012, Oncoimmunology.
[51] S. Shoin,et al. Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci. , 1967, Japanese journal of microbiology.
[52] A. Korman,et al. BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis In Vitro and Shows Antitumor Activity In Vivo in Hematologic Malignancies , 2012, Clinical Cancer Research.
[53] G. Anderson,et al. OX40 and CD30 signals in CD4+ T‐cell effector and memory function: a distinct role for lymphoid tissue inducer cells in maintaining CD4+ T‐cell memory but not effector function , 2011, Immunological reviews.
[54] P. O'dwyer,et al. Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), in advanced cancer patients. , 2012 .
[55] P. Hermonat,et al. AAV2/IL-12 gene delivery into dendritic cells (DC) enhances CTL stimulation above other IL-12 applications , 2012, Oncoimmunology.
[56] F. Di Virgilio,et al. Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice , 2011, Science.
[57] T. Wirth,et al. Gene therapy: the first approved gene-based medicines, molecular mechanisms and clinical indications. , 2008, Current molecular pharmacology.
[58] Bacterial vectors and delivery systems in cancer therapy. , 2010, IDrugs : the investigational drugs journal.
[59] S. Jalkanen,et al. Host CD73 impairs anti-tumor immunity , 2012, Oncoimmunology.
[60] R. Walter. Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia , 2014, Expert review of hematology.
[61] Michel C. Nussenzweig,et al. Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo , 2001, The Journal of experimental medicine.
[62] Milton W. Taylor,et al. Indoleamine 2,3-Dioxygenase Production by Human Dendritic Cells Results in the Inhibition of T Cell Proliferation , 2000, The Journal of Immunology.
[63] C. Wiltschke,et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] Tomohiro Watanabe,et al. Signalling pathways and molecular interactions of NOD1 and NOD2 , 2006, Nature Reviews Immunology.
[65] R. Orentas,et al. Lessons learned from a highly-active CD22-specific chimeric antigen receptor , 2013, Oncoimmunology.
[66] E. Gilboa,et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo , 1996, The Journal of experimental medicine.
[67] L. Galluzzi,et al. Current trends of anticancer immunochemotherapy , 2013, Oncoimmunology.
[68] J. Bluestone,et al. Interactions between programmed death-1 and programmed death ligand-1 promote tolerance by blocking the T cell receptor-induced stop signal , 2009, Nature Immunology.
[69] C. Melief,et al. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines , 2008, Nature Reviews Cancer.
[70] Michael L. Wang,et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.
[71] T. Sauerbruch,et al. Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model. , 2003, Cancer research.
[72] Cristina M. Tato,et al. SnapShot: Cytokines IV , 2008, Cell.
[73] M. Smyth,et al. Targeting cancer-derived adenosine: new therapeutic approaches. , 2014, Cancer discovery.
[74] C. Figdor,et al. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. , 2011, Blood.
[75] J. Wolchok,et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[76] B. Shalmon,et al. Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies , 2013, Clinical Cancer Research.
[77] L. Young,et al. Efficient nonviral transfection of dendritic cells and their use for in vivo immunization , 2000, Nature Biotechnology.
[78] W. Zong,et al. Chemotherapy induces tumor clearance independent of apoptosis. , 2008, Cancer research.
[79] N. Raje,et al. Thalidomide--a revival story. , 1999, The New England journal of medicine.
[80] A. Badiee,et al. Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205. , 2007, Vaccine.
[81] L. Zitvogel,et al. Targeting PD-1/PD-L1 interactions for cancer immunotherapy , 2012, Oncoimmunology.
[82] Toshihiko Ogura,et al. Identification of a Primary Target of Thalidomide Teratogenicity , 2010, Science.
[83] S. Loi. Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy , 2013, Oncoimmunology.
[84] Y. Urade,et al. Immunosuppression via adenosine receptor activation by adenosine monophosphate released from apoptotic cells , 2014, eLife.
[85] C. Demangel,et al. Targeting Dendritic Cells with Antigen-Containing Liposomes , 2004, Cancer Research.
[86] E. Kleinerman,et al. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] D. Filippov,et al. Efficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor Ligand–Peptide Conjugates , 2014, Cancer Immunology Research.
[88] E. Ruoslahti,et al. Enhanced Baculovirus-Mediated Transduction of Human Cancer Cells by Tumor-Homing Peptides , 2006, Journal of Virology.
[89] L. Zitvogel,et al. ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy , 2013, Oncoimmunology.
[90] J. Visvader,et al. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.
[91] Antoni Ribas,et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial , 2014, The Lancet.
[92] Michael Wang,et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. , 2007, The New England journal of medicine.
[93] Qing He,et al. CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.
[94] M. Erdmann. Immunity unleashed in melanoma. , 2010, The Lancet. Oncology.
[95] Cristina M. Tato,et al. SnapShot: Cytokines II , 2008, Cell.
[96] R. Ortíz-López,et al. Oncolytic virotherapy. , 2008, Annals of hepatology.
[97] S. Amigorena,et al. Antibody-dependent cell cytotoxicity in monoclonal antibody-mediated tumor immunotherapy , 2012, Oncoimmunology.
[98] Eric O Long. Negative signaling by inhibitory receptors: the NK cell paradigm , 2008, Immunological reviews.
[99] G. Prendergast,et al. IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. , 2014, International immunology.
[100] T. Ghansah. A novel strategy for modulation of MDSC to enhance cancer immunotherapy , 2012, Oncoimmunology.
[101] L. Falo,et al. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. , 1998, Journal of immunology.
[102] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[103] Dennie T. Frederick,et al. Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma , 2013, Oncoimmunology.
[104] L. Walker,et al. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses , 2011, Nature Reviews Immunology.
[105] Marianne Manchester,et al. Canine parvovirus-like particles, a novel nanomaterial for tumor targeting , 2006, Journal of nanobiotechnology.
[106] C. Janeway,et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. , 1998, Molecular cell.
[107] K. Partanen,et al. Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus , 2013, Clinical Cancer Research.
[108] S. Karasawa,et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide , 2012, Leukemia.
[109] B. Polack,et al. Live-attenuated bacteria as a cancer vaccine vector , 2013, Expert review of vaccines.
[110] L. Hart,et al. Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer , 2013, Cancer medicine.
[111] A. Lusis,et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. , 2010, Blood.
[112] Alessandro Corso,et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. , 2007, The New England journal of medicine.
[113] W. J. Ramsey,et al. A phase 2 study of docetaxel in combination with indoximod in metastatic breast cancer. , 2014 .
[114] R. Figlin,et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial , 2008, The Lancet.
[115] Ji Luo,et al. Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.
[116] R. Levy,et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. , 2019, The Journal of clinical investigation.
[117] L. Rimsza,et al. Efficacy of lenalidomide in myelodysplastic syndromes. , 2005, The New England journal of medicine.
[118] M. Croft. The role of TNF superfamily members in T-cell function and diseases , 2009, Nature Reviews Immunology.
[119] S. Scott,et al. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma. , 1998, Cancer practice.
[120] M. Caligiuri,et al. Uncovering a novel mechanism whereby NK cells interfere with glioblastoma virotherapy , 2013, Oncoimmunology.
[121] J. Leong,et al. Gene expression in rainbow trout (Oncorhynchus mykiss) following intramuscular injection of DNA. , 1996, Molecular marine biology and biotechnology.
[122] M. Smyth,et al. NKT cell adjuvants in therapeutic vaccines against hematological cancers , 2013, Oncoimmunology.
[123] A. Eggermont,et al. 20 Years Experience of TNF-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases: TNF Dose Matters , 2011, Annals of Surgical Oncology.
[124] A. Tong,et al. Antitumor Activity of an Oncolytic Adenoviral-CD40 Ligand (CD154) Transgene Construct in Human Breast Cancer Cells , 2009, Clinical Cancer Research.
[125] T. Lynch,et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[126] L. Galluzzi,et al. Rejuvenated T cells attack old tumors , 2013, Oncoimmunology.
[127] G. Dranoff,et al. Combining immunotherapy and targeted therapies in cancer treatment , 2012, Nature Reviews Cancer.
[128] P. Greenberg,et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. , 2006, The New England journal of medicine.
[129] Maria Papatriantafyllou. Cytokines: True to their family name , 2013, Nature Reviews Immunology.
[130] P. O'dwyer,et al. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies. , 2013 .
[131] A. Ribas,et al. MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro. , 2010, Clinical immunology.
[132] S. Vogel,et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming , 2007, Proceedings of the National Academy of Sciences.
[133] Kelvin K. W. Chan,et al. Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[134] L. Galluzzi,et al. Mitochondria: master regulators of danger signalling , 2012, Nature Reviews Molecular Cell Biology.
[135] S. Fahrenkrug,et al. Genetic immunization of rainbow trout (Oncorhynchus mykiss) against infectious hematopoietic necrosis virus. , 1996, Molecular marine biology and biotechnology.
[136] O. Wildner,et al. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. , 1999, Cancer research.
[137] Stephen Mok,et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. , 2013, Cancer research.
[138] J. Landsberg,et al. Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity , 2012, Oncoimmunology.
[139] Jeffrey A Jones,et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. , 2014, The Lancet. Oncology.
[140] I. Melero,et al. Therapeutic vaccines for cancer: an overview of clinical trials , 2014, Nature Reviews Clinical Oncology.
[141] A. Sarnaik,et al. Continuous 4–1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy , 2013, Oncoimmunology.
[142] Matthew G. Vander Heiden,et al. Metabolic targets for cancer therapy , 2013, Nature Reviews Drug Discovery.
[143] T. Curiel,et al. Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.
[144] Michael R. Elliott,et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance , 2009, Nature.
[145] Yonghong Wan,et al. HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[146] A. Rosenwald,et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. , 2014, The Lancet. Oncology.
[147] S. Gottschalk,et al. Design and development of therapies using chimeric antigen receptor‐expressing T cells , 2014, Immunological reviews.
[148] A. Eliopoulos,et al. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. , 2012, Cancer research.
[149] C. Yun,et al. Oncolytic Adenovirus Expressing IL-23 and p35 Elicits IFN-γ- and TNF-α-Co-Producing T Cell-Mediated Antitumor Immunity , 2013, PloS one.
[150] M. Shurin,et al. Conference overview: Cancer Immunotherapy and Immunomonitoring (CITIM): Moving forward , 2012, Journal of immunotoxicology.
[151] R. Ferris,et al. Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients , 2013, Clinical Cancer Research.
[152] J. Fucikova,et al. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. , 2011, Cancer research.
[153] S. Antonia,et al. Overcoming tumor antigen anergy in human malignancies using the novel indeolamine 2,3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-D-tryptophan (1MT). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[154] N. Cheung,et al. Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[155] C. Liu,et al. Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion , 2013, Nature Medicine.
[156] H. Weiner,et al. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell–like and Foxp3+ regulatory T cells , 2010, Nature Immunology.
[157] William J. Buchser,et al. Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands , 2012, Oncoimmunology.
[158] G. Prendergast,et al. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase , 2008, Proceedings of the National Academy of Sciences.
[159] W. J. Ramsey,et al. A phase I study of indoximod in combination with docetaxel in metastatic solid tumors. , 2013 .
[160] I. Pastan,et al. A novel bispecific antibody recruits T cells to eradicate tumors in the “immunologically privileged” central nervous system , 2013, Oncoimmunology.
[161] Jennifer Couzin-Frankel,et al. Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.
[162] Liang Zhang,et al. Maraba virus as a potent oncolytic vaccine vector. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[163] J. Shimizu,et al. Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance , 2002, Nature Immunology.
[164] Sylvia Janetzki,et al. Harmonization of Immune Biomarker Assays for Clinical Studies , 2011, Science Translational Medicine.
[165] S. Demaria,et al. Select forms of tumor cell apoptosis induce dendritic cell maturation , 2005, Journal of leukocyte biology.
[166] P. van Endert,et al. Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death , 2009, The EMBO journal.
[167] A. Eggermont,et al. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[168] G. Plosker. Sipuleucel-T , 2012, Drugs.
[169] Dirk E. Smith,et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction , 2001, Nature.
[170] Wei Zhang,et al. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer , 2006, Cancer Gene Therapy.
[171] A. Eggermont,et al. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. , 2006, The oncologist.
[172] F. Macian,et al. Uncovering the mechanisms that regulate tumor-induced T-cell anergy , 2013, Oncoimmunology.
[173] Gregory I. Elliott,et al. 3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis , 2007, Proceedings of the National Academy of Sciences.
[174] N. Fusenig,et al. Friends or foes — bipolar effects of the tumour stroma in cancer , 2004, Nature Reviews Cancer.
[175] C. Figdor,et al. Dendritic cell immunotherapy: mapping the way , 2004, Nature Medicine.
[176] Louis M. Weiner,et al. Building better magic bullets — improving unconjugated monoclonal antibody therapy for cancer , 2007, Nature Reviews Cancer.
[177] E. Tartour,et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. , 2013, Cancer research.
[178] A. Coxon,et al. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types , 2010, Cancer biology & therapy.
[179] L. Zitvogel,et al. Immunological effects of chemotherapy in spontaneous breast cancers , 2013, Oncoimmunology.
[180] S. Ferrone,et al. Abstract 632: Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing , 2014 .
[181] V. Kuchroo,et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression , 2007, The Journal of experimental medicine.
[182] J. Vincent,et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. , 2010, Cancer research.
[183] Derek L. Clouthier,et al. Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+ T-cell responses to anticancer vaccines , 2013, Oncoimmunology.
[184] Michel Sadelain,et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.
[185] M. Mason,et al. Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production , 2011, The Journal of Immunology.
[186] A. Bovier,et al. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? , 2013, Nature Reviews Cancer.
[187] D. McNeel,et al. Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence , 2012, Expert review of vaccines.
[188] Cristina M. Tato,et al. SnapShot: Cytokines I , 2008, Cell.
[189] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[190] C. Horak,et al. Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.
[191] M. Kadin,et al. Targeted therapies: Denileukin diftitox—a step towards a 'magic bullet' for CTCL , 2010, Nature Reviews Clinical Oncology.
[192] Kateřina Pokorná,et al. Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials , 2011, Journal of Translational Medicine.
[193] D. Keskin,et al. Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase , 2002, Science.
[194] R. Lehmann,et al. An armed oncolytic measles vaccine virus eliminates human hepatoma cells independently of apoptosis , 2013, Gene Therapy.
[195] L. Boon,et al. Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine. , 2011, Cancer research.
[196] H. Wakimoto,et al. Complement Depletion Facilitates the Infection of Multiple Brain Tumors by an Intravascular, Replication-Conditional Herpes Simplex Virus Mutant , 2000, Journal of virology.
[197] S. Kim-Schulze,et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[198] G. Grau,et al. Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states. , 1991, Clinical and experimental immunology.
[199] P. Hwu,et al. Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer , 2013, Oncoimmunology.
[200] P. Vandenabeele,et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death , 2012, The EMBO journal.
[201] Michael Dean,et al. Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.
[202] P. Brouckaert,et al. Extracellular ATP drives systemic inflammation, tissue damage and mortality , 2014, Cell Death and Disease.
[203] D. Bigner,et al. Bone Marrow–generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors , 1997, The Journal of experimental medicine.
[204] C. Wysocki,et al. Development of amphotropic murine retrovirus vectors resistant to inactivation by human serum. , 1996, Human gene therapy.
[205] A. Nowak. Immunological checkpoint inhibitors enter adolescence. , 2013, The Lancet. Oncology.
[206] R. Flavell,et al. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 , 2001, Nature.
[207] S. Bagcchi. Pembrolizumab for treatment of refractory melanoma. , 2014, The Lancet. Oncology.
[208] P. Validire,et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. , 2010, The Journal of clinical investigation.
[209] W. Murphy,et al. Immunoediting and Antigen Loss: Overcoming the Achilles Heel of Immunotherapy with Antigen Non-Specific Therapies , 2013, Front. Oncol..
[210] M. Brown,et al. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer , 2013, Journal of Hematology & Oncology.
[211] S. Jagannath,et al. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. , 2007, Blood.
[212] L. Zitvogel,et al. The secret ally: immunostimulation by anticancer drugs , 2012, Nature Reviews Drug Discovery.
[213] R. Orentas,et al. Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. , 2001, Cellular immunology.
[214] Michel C. Nussenzweig,et al. Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell Tolerance , 2002, The Journal of experimental medicine.
[215] M. Zucchetti,et al. Role of macrophage targeting in the antitumor activity of trabectedin. , 2013, Cancer cell.
[216] T. Salo,et al. Toll-like receptor 5 (TLR5) expression is a novel predictive marker for recurrence and survival in squamous cell carcinoma of the tongue , 2013, British Journal of Cancer.
[217] L. Galluzzi,et al. Immune effectors required for the therapeutic activity of vorinostat , 2013, Oncoimmunology.
[218] W. Curran. The thalidomide tragedy in Germany: the end of a historic medicolegal trial. , 1971, The New England journal of medicine.
[219] D. Schadendorf,et al. Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.
[220] Laurence Zitvogel,et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes , 1998, Nature Medicine.
[221] H. Arakawa,et al. Fusions between dendritic cells and whole tumor cells as anticancer vaccines , 2013, Oncoimmunology.
[222] S. Rosenberg,et al. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. , 2006, Blood.
[223] P. Coulie,et al. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy , 2014, Nature Reviews Cancer.
[224] Donald Kennedy,et al. Breakthrough of the Year , 2007, Science.
[225] Sjoerd H van der Burg,et al. Design and development of synthetic peptide vaccines: past, present and future , 2007, Expert review of vaccines.
[226] L. Zitvogel,et al. The Critical Role of IL-15 in the Antitumor Effects Mediated by the Combination Therapy Imatinib and IL-21 , 2008, The Journal of Immunology.
[227] C. Figdor,et al. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. , 2005, Blood.
[228] L. Galluzzi,et al. Novel immune checkpoint blocker approved for the treatment of advanced melanoma , 2014, Oncoimmunology.
[229] George Coukos,et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.
[230] J. Garcia-Vallejo,et al. Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines , 2013, Oncoimmunology.
[231] A. Bolhassani,et al. Therapeutic live vaccines as a potential anticancer strategy , 2012, International journal of cancer.
[232] S. Rosenberg,et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[233] F. Schuetz,et al. B cell-regulated immune responses in tumor models and cancer patients , 2013, Oncoimmunology.
[234] L. Zitvogel,et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress , 2011, Oncogene.
[235] B. Rouse,et al. Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells , 1997, Journal of leukocyte biology.
[236] R. Sorrentino,et al. The adenosinergic system in cancer , 2013, Oncoimmunology.
[237] L. Zitvogel,et al. Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer , 2012, Oncoimmunology.
[238] Federica Cavallo,et al. Are oncoantigens suitable targets for anti-tumour therapy? , 2007, Nature Reviews Cancer.
[239] Jens-Peter Volkmer,et al. Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies , 2013, Science.
[240] Steven A. Rosenberg,et al. Adoptive immunotherapy for cancer: harnessing the T cell response , 2012, Nature Reviews Immunology.
[241] M. Lotze,et al. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. , 1999, Cancer research.
[242] K. Ulbrich,et al. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies , 2001, Gene Therapy.
[243] M. Gordon. Efficacy of Lenalidomide in Myelodysplastic Syndromes , 2006 .
[244] S. Rosenberg,et al. Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression , 2011, Clinical Cancer Research.
[245] J. Gołąb,et al. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. , 2011, Frontiers in bioscience.
[246] G. Trinchieri,et al. Ligand and cytokine dependence of the immunosuppressive pathway of tryptophan catabolism in plasmacytoid dendritic cells. , 2005, International immunology.
[247] J. Wolchok,et al. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps , 2011, Nature Reviews Cancer.
[248] G. Dranoff. Immunotherapy at Large: Balancing tumor immunity and inflammatory pathology , 2013, Nature Medicine.
[249] G. Belz,et al. Cross‐presentation, dendritic cell subsets, and the generation of immunity to cellular antigens , 2004, Immunological reviews.
[250] S. Rosenberg,et al. Telomere Length of Transferred Lymphocytes Correlates with In Vivo Persistence and Tumor Regression in Melanoma Patients Receiving Cell Transfer Therapy1 , 2005, The Journal of Immunology.
[251] Lorenzo Galluzzi,et al. Metabolic control of cell death , 2014, Science.
[252] Christopher J. Ott,et al. The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins , 2014, Science.
[253] Miriam Merad,et al. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. , 2013, Annual review of immunology.
[254] B. Levine,et al. Adoptive immunotherapy for cancer or viruses. , 2014, Annual review of immunology.
[255] E. Tartour,et al. NK cells from pleural effusions are potent antitumor effector cells , 2013, European journal of immunology.
[256] Karolina Palucka,et al. Cancer immunotherapy via dendritic cells , 2012, Nature Reviews Cancer.
[257] E. Gilboa. DC-based cancer vaccines. , 2007, The Journal of clinical investigation.
[258] L. Frati,et al. Activation of dendritic cells by tumor cell death , 2012, Oncoimmunology.
[259] Laura Conti,et al. The noninflammatory role of high mobility group box 1/toll‐like receptor 2 axis in the self‐renewal of mammary cancer stem cells , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[260] Mauricio Leal,et al. Antibody–drug conjugates: an emerging modality for the treatment of cancer , 2014, Annals of the New York Academy of Sciences.
[261] O. Kepp,et al. Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling , 2013, Cell Death and Differentiation.
[262] I. Weissman,et al. Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPα variants , 2013, Oncoimmunology.
[263] Katia Perruccio,et al. Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.
[264] J. O’Sullivan,et al. Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment , 2012, Oncoimmunology.
[265] M. Karamouzis,et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer , 2010, Cancer Immunology, Immunotherapy.
[266] S. Mattarollo,et al. Combining low-dose or metronomic chemotherapy with anticancer vaccines , 2013, Oncoimmunology.
[267] S. Demaria,et al. The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer , 2013, Oncoimmunology.
[268] H. Kohrt,et al. Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody , 2012, Oncoimmunology.
[269] H. Lyerly,et al. CPG-7909 (PF-3512676, ProMune®): toll-like receptor-9 agonist in cancer therapy , 2007, Expert opinion on biological therapy.
[270] L. Coussens,et al. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. , 2005, Cancer cell.
[271] L. Zitvogel,et al. Trial Watch , 2014, Oncoimmunology.
[272] J. Engh,et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[273] I. Svane,et al. The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+ T cells , 2013, Oncoimmunology.
[274] L. Zitvogel,et al. Trial Watch-Oncolytic viruses and cancer therapy. , 2016 .
[275] E. Pfefferkorn. Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[276] A. Ribas,et al. Immunomodulation by imiquimod in patients with high-risk primary melanoma , 2011, The Journal of investigative dermatology.
[277] H. Abken,et al. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells , 2012, Oncoimmunology.
[278] S. Olivares,et al. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. , 2011, Cancer research.
[279] N. Schmitz,et al. Generation of Cytotoxic Responses in Mice and Human Individuals Against Hematological Malignancies Using Survivin-RNA-Transfected Dendritic Cells1 , 2003, Journal of Immunology.
[280] E. Morselli,et al. Viral Control of Mitochondrial Apoptosis , 2008, PLoS pathogens.
[281] O. Hayaishi,et al. Induction of pulmonary indoleamine 2,3-dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide. , 1978, Proceedings of the National Academy of Sciences of the United States of America.
[282] R. Figlin,et al. Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies , 2008, Clinical Cancer Research.
[283] D. Munn,et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. , 1998, Science.
[284] M. Albert,et al. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs , 1998, Nature.
[285] L. Zitvogel,et al. Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39 , 2012, Oncoimmunology.
[286] F. Végran,et al. Bleomycin Exerts Ambivalent Antitumor Immune Effect by Triggering Both Immunogenic Cell Death and Proliferation of Regulatory T Cells , 2013, PloS one.
[287] M. Moreno,et al. Salmonella as live trojan horse for vaccine development and cancer gene therapy. , 2010, Current gene therapy.
[288] S. Bertholet,et al. Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants , 2014, Proceedings of the National Academy of Sciences.
[289] Laurence Zitvogel,et al. Immunogenic cell death in cancer therapy. , 2013, Annual review of immunology.
[290] L. Zitvogel,et al. Trans-Presentation of IL-15 Dictates IFN-Producing Killer Dendritic Cells Effector Functions1 , 2008, The Journal of Immunology.
[291] D. Raulet,et al. Oncogenic stress sensed by the immune system: role of natural killer cell receptors , 2009, Nature Reviews Immunology.
[292] J. Nitadori,et al. Prognostic value of the immune microenvironment in lung adenocarcinoma , 2013, Oncoimmunology.
[293] A. Barber,et al. Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors , 2013, Oncoimmunology.
[294] Drew M. Pardoll,et al. Immunostimulatory monoclonal antibodies for cancer therapy , 2007, Nature Reviews Cancer.
[295] S. Akira,et al. Role of Adaptor TRIF in the MyD88-Independent Toll-Like Receptor Signaling Pathway , 2003, Science.
[296] L. Bracci,et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. , 2011, Cancer research.
[297] Bryony Jones. Haematological cancer: Rituximab maintenance improves the outcome of elderly patients with FL , 2013, Nature Reviews Clinical Oncology.
[298] D. Torigian,et al. Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies , 2013, Cancer Immunology Research.
[299] I. Hellstrom,et al. Curing Mice with Large Tumors by Locally Delivering Combinations of Immunomodulatory Antibodies , 2014, Clinical Cancer Research.
[300] J. Pignon,et al. Immunogenic death of colon cancer cells treated with oxaliplatin , 2010, Oncogene.
[301] Di Chen,et al. Silencing IDO in dendritic cells: A novel approach to enhance cancer immunotherapy in a murine breast cancer model , 2013, International journal of cancer.
[302] Amber J. Giles,et al. Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy , 2014, Science Translational Medicine.
[303] L. Zitvogel,et al. Trial watch: IDO inhibitors in cancer therapy , 2014, Oncoimmunology.
[304] D. Ladant,et al. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. , 2007, Cancer research.
[305] L. Zitvogel,et al. Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death , 2012, Science Translational Medicine.
[306] P. Duewell,et al. Breaking tumor-induced immunosuppression with 5′-triphosphate siRNA silencing TGFβ and activating RIG-I , 2013, Oncoimmunology.
[307] P. MacAry,et al. CD137L-stimulated dendritic cells are more potent than conventional dendritic cells at eliciting cytotoxic T-cell responses , 2013, Oncoimmunology.
[308] R. Tyagi,et al. RNA pulsed dendritic cells: an approach for cancer immunotherapy. , 2013, Vaccine.
[309] L. Hoffman,et al. Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE® Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications , 2014, Front. Oncol..
[310] S. Lonial,et al. Clinical uses of GM-CSF, a critical appraisal and update , 2008, Biologics : targets & therapy.
[311] R. Schreiber,et al. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.
[312] H. Einsele,et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. , 2012, Blood.
[313] P. Vandenabeele,et al. Consensus guidelines for the detection of immunogenic cell death , 2014, Oncoimmunology.
[314] R. Steinman,et al. In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination , 2004, The Journal of experimental medicine.
[315] L. Galluzzi,et al. Novel insights into the mechanism of action of lenalidomide , 2014, Oncoimmunology.
[316] M. Capogrossi,et al. Age-dependent effects of repeated immunization with a first generation adenovirus vector on the immune response and transgene expression in young and old rats , 2002, Experimental Gerontology.
[317] R. Poole. Pembrolizumab: First Global Approval , 2014, Drugs.
[318] Ruslan Medzhitov,et al. Pattern recognition receptors and control of adaptive immunity , 2009, Immunological reviews.
[319] A. Chang,et al. Adoptive Transfer of Tumor Reactive B Cells Confers Host T-Cell Immunity and Tumor Regression , 2011, Clinical Cancer Research.
[320] Antoni Ribas,et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.
[321] Haidong Dong,et al. Immunomodulatory Antibody Therapy of Cancer: The Closer, the Better , 2014, Clinical Cancer Research.
[322] Steven A. Rosenberg,et al. Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know , 2011, Nature Reviews Clinical Oncology.
[323] A. D. Van den Abbeele,et al. Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma , 2014, Cancer Immunology Research.
[324] D. Schadendorf,et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. , 2010, The Lancet. Oncology.
[325] J. Couzin. Small RNAs Make Big Splash , 2002, Science.
[326] J. Hiscott,et al. Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy , 2011, Cancer Gene Therapy.
[327] D. Klinman,et al. Potential of Transfected Muscle Cells to Contribute to DNA Vaccine Immunogenicity1 , 2007, The Journal of Immunology.
[328] A. Calcinotto,et al. Boosting anticancer vaccines , 2013, Oncoimmunology.
[329] Lorenzo Galluzzi,et al. Molecular mechanisms of regulated necrosis. , 2014, Seminars in cell & developmental biology.
[330] BioBusiness Briefs. Trial watch: Ipilimumab success in melanoma provides boost for cancer immunotherapy , 2010, Nature Reviews Drug Discovery.
[331] L. Galluzzi,et al. Immunogenic cell death in radiation therapy , 2013, Oncoimmunology.
[332] S. Rosenberg,et al. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors , 2013, Nature Reviews Clinical Oncology.
[333] T. Bozanovic,et al. Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer , 2012, Oncoimmunology.
[334] H. Arakawa,et al. Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions , 2013, Oncoimmunology.
[335] A. Parker,et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. , 2012, Cancer cell.
[336] Bob Löwenberg,et al. Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. , 2012, Blood.
[337] S. Rosenberg,et al. Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.
[338] B. Fox,et al. Autophagy-assisted antigen cross-presentation , 2012, Oncoimmunology.
[339] Lieping Chen,et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors , 1997, Nature Medicine.
[340] S. Larson,et al. Tumor-specific in vivo transfection with HSV-1 thymidine kinase gene using a Sindbis viral vector as a basis for prodrug ganciclovir activation and PET. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[341] F. Tangy,et al. Natural Oncolytic Activity of Live-Attenuated Measles Virus against Human Lung and Colorectal Adenocarcinomas , 2013, BioMed research international.
[342] S. Martin,et al. Danger signalling during cancer cell death: origins, plasticity and regulation , 2013, Cell Death and Differentiation.
[343] D. Mann,et al. Clinical response of advanced cancer patients to cellular immunotherapy and intensity-modulated radiation therapy , 2013, Oncoimmunology.
[344] J. Schachter,et al. Development of Allogeneic NK Cell Adoptive Transfer Therapy in Metastatic Melanoma Patients: In Vitro Preclinical Optimization Studies , 2013, PloS one.
[345] D. Niedzwiecki,et al. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. , 2008, Blood.
[346] Jens-Peter Volkmer,et al. Anti-CD47 antibody–mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response , 2013, Proceedings of the National Academy of Sciences.
[347] J. Banchereau,et al. Dendritic-cell-based therapeutic cancer vaccines. , 2013, Immunity.
[348] E. Tartour,et al. An allogeneic NK cell line engineered to express chimeric antigen receptors , 2013, Oncoimmunology.
[349] P. Zipfel,et al. Complement regulators and inhibitory proteins , 2009, Nature Reviews Immunology.
[350] Michel Sadelain,et al. Targeting tumours with genetically enhanced T lymphocytes , 2003, Nature Reviews Cancer.
[351] S. Akira,et al. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. , 2011, Immunity.
[352] C. Cohen,et al. Genetically modulating T-cell function to target cancer. , 2012, Seminars in cancer biology.
[353] L. Kaiser,et al. Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity , 2005, Clinical Cancer Research.
[354] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[355] T. Ito,et al. Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors , 2012, Cancer Gene Therapy.
[356] Hideo Negishi,et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses , 2005, Nature.
[357] S. Elledge,et al. Non-Oncogene Addiction and the Stress Phenotype of Cancer Cells , 2007, Cell.
[358] D. Raulet,et al. Regulation of NK cell responsiveness to achieve self‐tolerance and maximal responses to diseased target cells , 2008, Immunological reviews.
[359] L. Zitvogel,et al. Trial watch , 2013 .
[360] P. Vandenabeele,et al. Regulated necrosis: the expanding network of non-apoptotic cell death pathways , 2014, Nature Reviews Molecular Cell Biology.
[361] C. Haglund,et al. TLR-4 expression and decrease in chronic inflammation: indicators of aggressive follicular thyroid carcinoma , 2012, Journal of Clinical Pathology.
[362] V. Chiarion-Sileni,et al. Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response , 2013, Cancer Immunology, Immunotherapy.
[363] D Andrews,et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015 , 2014, Cell Death and Differentiation.
[364] Ya-jun Guo,et al. Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy , 2014, Oncoimmunology.
[365] Margaret A. Liu. DNA vaccines: an historical perspective and view to the future , 2011, Immunological reviews.
[366] S. Rosenberg,et al. Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma , 2005, Journal of immunotherapy.
[367] M. Bloomston,et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer , 2013, Nature Medicine.
[368] Kenneth J. Hillan,et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.
[369] S. Rosenberg,et al. Prevention of Interleukin-2 Withdrawal-Induced Apoptosis in Lymphocytes Retrovirally Cotransduced With Genes Encoding an Antitumor T-cell Receptor and an Antiapoptotic Protein , 2010, Journal of immunotherapy.
[370] L. Zitvogel,et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy , 2011, Cancer and Metastasis Reviews.
[371] T. Whiteside,et al. Elimination of established liver metastases by human interleukin 2-activated natural killer cells after locoregional or systemic adoptive transfer. , 1996, Cancer research.
[372] S. Balachandran,et al. Development of interferon γ-based immunocytokines targeting renal cancer , 2013, Oncoimmunology.
[373] C. Figdor,et al. Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation. , 2011, Blood.
[374] M. Smyth,et al. Adoptive Transfer of Gene-Modified Primary NK Cells Can Specifically Inhibit Tumor Progression In Vivo1 , 2008, The Journal of Immunology.
[375] W. den Otter,et al. Therapeutic response of untreatable hepatocellular carcinoma after application of the immune modulators IL-2, BCG and melatonin. , 2013, Anticancer research.
[376] C. Punt,et al. Cancer immunotherapy – revisited , 2011, Nature Reviews Drug Discovery.
[377] S. Abrams,et al. © 2012 Landes Bioscience. Do not distribute. Identification of a G-CSF-Granulocytic MDSC axis that promotes tumor progression , 2012 .
[378] G. Freeman,et al. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. , 2013, The Journal of clinical investigation.
[379] J. Kowalski,et al. K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate , 2010, Clinical Cancer Research.
[380] R. Ferris,et al. TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR+ head and neck cancer cells , 2013, Oncoimmunology.
[381] E. Mittendorf,et al. Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer. , 2006, Surgery.
[382] A. Deisseroth,et al. Oncolytic adenoviral vector carrying the cytosine deaminase gene for melanoma gene therapy , 2006, Cancer Gene Therapy.
[383] G. Prendergast,et al. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy , 2005, Nature Medicine.
[384] Martin Pule,et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. , 2011, Blood.
[385] J. Taube,et al. Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody , 2012, Clinical Cancer Research.
[386] A. Aruga. Vaccination of biliary tract cancer patients with four peptides derived from cancer-testis antigens , 2013, Oncoimmunology.
[387] L. Zitvogel,et al. Trial Watch , 2012, Oncoimmunology.
[388] Rakesh K. Jain,et al. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases , 2011, Nature Reviews Drug Discovery.
[389] L. Galluzzi,et al. Impact of myeloid cells on the efficacy of anticancer chemotherapy. , 2014, Current opinion in immunology.
[390] E. Lipson. Re-orienting the immune system , 2013, Oncoimmunology.
[391] G. Prendergast,et al. IDO is a nodal pathogenic driver of lung cancer and metastasis development. , 2012, Cancer discovery.
[392] S. Carr,et al. Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells , 2014, Science.
[393] P. Mclaughlin,et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. , 2012, The Lancet. Oncology.
[394] W. Shen,et al. Oncolytic adenovirus mediated Survivin RNA interference and 5-fluorouracil synergistically suppress the lymphatic metastasis of colorectal cancer. , 2010, Oncology reports.
[395] Courtney Humphries,et al. Adoptive cell therapy: Honing that killer instinct , 2013, Nature.
[396] Nicolas André,et al. Metronomic chemotherapy: new rationale for new directions , 2010, Nature Reviews Clinical Oncology.
[397] P. Kokhaei,et al. Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell–tumour hybrids in B-CLL , 2003, Leukemia.
[398] H. Fujii,et al. Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. , 2012, Cancer research.
[399] H. Goldschmidt,et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. , 2013, The Lancet. Oncology.
[400] C. Ottensmeier,et al. DNA vaccines: precision tools for activating effective immunity against cancer , 2008, Nature Reviews Cancer.
[401] B. Barlogie,et al. Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.
[402] Ira Mellman,et al. Designing vaccines based on biology of human dendritic cell subsets. , 2010, Immunity.
[403] Alberto Mantovani,et al. Macrophage plasticity and polarization: in vivo veritas. , 2012, The Journal of clinical investigation.
[404] Jonathan B. Mitchem,et al. Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis , 2013, Clinical Cancer Research.
[405] E. Deeks. Nivolumab: A Review of Its Use in Patients with Malignant Melanoma , 2014, Drugs.
[406] C. Blanpain,et al. Unravelling cancer stem cell potential , 2013, Nature Reviews Cancer.
[407] N. Warner,et al. Function of Nod‐like receptors in microbial recognition and host defense , 2009, Immunological reviews.
[408] C. Tinelli,et al. Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer , 2011, Oncology.
[409] F. Ghiringhelli,et al. The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy , 2014, Expert review of clinical immunology.
[410] L. Zitvogel,et al. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. , 2010, Cancer research.
[411] O. Delbono,et al. Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells , 2012, Oncoimmunology.
[412] M. Raffeld,et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[413] J. Wolchok,et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.
[414] Philippe Dessen,et al. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. , 2007, Cancer research.
[415] J. Blay,et al. Plasmacytoid dendritic cells deficient in IFNα production promote the amplification of FOXP3+ regulatory T cells and are associated with poor prognosis in breast cancer patients , 2013, Oncoimmunology.
[416] A. Marzo,et al. Adoptive T-cell transfer combined with a single low dose of total body irradiation eradicates breast tumors , 2013, Oncoimmunology.
[417] A. Asai,et al. Adenovirus-mediated transfer of p53 and Fas ligand drastically enhances apoptosis in gliomas , 2000, Cancer Gene Therapy.
[418] D. Linehan,et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. , 2015, Cancer research.
[419] L. Zitvogel,et al. Cancer despite immunosurveillance: immunoselection and immunosubversion , 2006, Nature Reviews Immunology.
[420] Lieping Chen. Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity , 2004, Nature Reviews Immunology.
[421] M. Iadarola,et al. A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. , 1975, The Journal of infectious diseases.
[422] S. H. van der Burg,et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. , 2009, The New England journal of medicine.
[423] A. Irisawa,et al. Phase I trial of preoperative intratumoral injection of immature dendritic cells and OK-432 for resectable pancreatic cancer patients , 2012, Journal of hepato-biliary-pancreatic sciences.
[424] D. Bartlett,et al. Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity. , 2012, Neoplasia.
[425] Louis M. Weiner,et al. Monoclonal antibodies: versatile platforms for cancer immunotherapy , 2010, Nature Reviews Immunology.
[426] O. Ilhan,et al. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony‐stimulating factor (rhG‐CSF): a randomized evaluation of different doses of rhG‐CSF , 2002, British journal of haematology.
[427] B. Bonnotte,et al. Cytotoxic Dendritic Cells Generated from Cancer Patients , 2011, The Journal of Immunology.
[428] P. Hwu,et al. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. , 2014, The Journal of clinical investigation.
[429] Jeff E. Mold,et al. Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of TH17 to Regulatory T Cells in HIV Disease , 2010, Science Translational Medicine.
[430] C. Uyttenhove,et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.
[431] H. Schreiber,et al. High-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodies , 2013, Oncoimmunology.
[432] M. Smyth,et al. Supernatural T cells: genetic modification of T cells for cancer therapy , 2005, Nature Reviews Immunology.
[433] G. Tocco,et al. Differential Effects of Denileukin Diftitox IL-2 Immunotoxin on NK and Regulatory T Cells in Nonhuman Primates , 2012, The Journal of Immunology.
[434] Adrian Ozinsky,et al. Phagocytosis of microbes: complexity in action. , 2002, Annual review of immunology.
[435] K. Wellen,et al. A two-way street: reciprocal regulation of metabolism and signalling , 2012, Nature Reviews Molecular Cell Biology.
[436] P. van Endert,et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. , 2013, Immunity.
[437] S. Rosenberg,et al. Transduction of an IL-2 Gene into Human Melanoma-Reactive Lymphocytes Results in Their Continued Growth in the Absence of Exogenous IL-2 and Maintenance of Specific Antitumor Activity , 2001, The Journal of Immunology.
[438] R. Davis,et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. , 2014, The Lancet. Oncology.
[439] Lieping Chen,et al. Inhibitory B7-family molecules in the tumour microenvironment , 2008, Nature Reviews Immunology.
[440] E. Gilboa,et al. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. , 2000, Cancer research.
[441] C. Ottensmeier,et al. DNA vaccines against cancer come of age. , 2010, Current opinion in immunology.
[442] Simon C Watkins,et al. Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. , 2002, Journal of experimental therapeutics & oncology.
[443] I. Vergote,et al. Dendritic cell-based immunotherapy in ovarian cancer , 2013, Oncoimmunology.
[444] E. Condom,et al. High Expression of Ecto-Nucleotidases CD39 and CD73 in Human Endometrial Tumors , 2014, Mediators of inflammation.
[445] E. Klechevsky,et al. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. , 2010, Blood.
[446] B. Baban,et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. , 2005, Immunity.
[447] W. Storkus,et al. B 7 Cost imulat ion , and T Helper Cell 1-associated Cytokines , 2003 .
[448] M. Millenson,et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.
[449] I. Svane,et al. Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase , 2013, Clinical Cancer Research.
[450] L. Galluzzi,et al. Enlightening the impact of immunogenic cell death in photodynamic cancer therapy , 2012, The EMBO journal.
[451] C. Figdor,et al. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. , 2012, Blood.
[452] G. Bepler,et al. Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[453] Hiroaki Tanaka,et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival , 2012, Nature Medicine.
[454] E. Shevach,et al. The GITR–GITRL interaction: co-stimulation or contrasuppression of regulatory activity? , 2006, Nature Reviews Immunology.
[455] Lai Wei,et al. Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer , 2013, Cancer biology & therapy.
[456] M. Vähä-Koskela,et al. Oncolytic viruses in cancer therapy , 2007, Cancer Letters.
[457] Hong-fen Guo,et al. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo , 2012, Oncoimmunology.
[458] P. Ascierto,et al. Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination , 2013, Clinical Cancer Research.
[459] A. Mansfield,et al. The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma , 2013, Oncoimmunology.
[460] Abhishek D. Garg,et al. Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin , 2012, Cancer Immunology, Immunotherapy.
[461] J. Eliaou,et al. ENTPD1/CD39 is a promising therapeutic target in oncology , 2013, Oncogene.
[462] J. Fisher,et al. A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours , 2013, Journal of chemotherapy.
[463] J. Fechner,et al. An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells , 2010, The Journal of Immunology.
[464] H. Redmond,et al. Links between Toll-like receptor 4 and breast cancer , 2013, Oncoimmunology.
[465] G. Kaplan,et al. Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. , 1996, Journal of medicinal chemistry.
[466] D. O'hagan,et al. Designing and building the next generation of improved vaccine adjuvants. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[467] P. Allavena,et al. Trabectedin , 2013, Oncoimmunology.
[468] R. Medzhitov,et al. Toll-like receptors and cancer , 2009, Nature Reviews. Cancer.
[469] G. Gibney,et al. Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. , 2014 .
[470] Abhishek D. Garg,et al. Immunogenic cell death and DAMPs in cancer therapy , 2012, Nature Reviews Cancer.
[471] V. Deretic,et al. Autophagy and pattern recognition receptors in innate immunity , 2009, Immunological reviews.
[472] L. Galluzzi,et al. Decoding cell death signals in liver inflammation. , 2013, Journal of hepatology.
[473] K. Partanen,et al. Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. , 2012, Cancer research.
[474] H. Kohrt,et al. Targeting CD137 enhances the efficacy of cetuximab. , 2014, The Journal of clinical investigation.
[475] S. Alkan,et al. Monoclonal antibodies: the story of a discovery that revolutionized science and medicine , 2004, Nature Reviews Immunology.
[476] W. Burns,et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. , 2011, Blood.
[477] Dung-Tsa Chen,et al. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer , 2013, Cancer Immunology, Immunotherapy.
[478] J. Isaacs,et al. The quinoline‐3‐carboxamide anti‐angiogenic agent, tasquinimod, enhances the anti‐prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts , 2007, The Prostate.
[479] P. Kantoff,et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.
[480] B. Robinson,et al. Immunotherapy and chemotherapy — a practical partnership , 2005, Nature Reviews Cancer.
[481] P. Ricciardi-Castagnoli,et al. Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo , 1999, Nature Medicine.
[482] T. Giese,et al. Predictive immunomonitoring -- the COST ENTIRE initiative. , 2013, Clinical Immunology.
[483] Bin Zhang. CD73 promotes tumor growth and metastasis , 2012, Oncoimmunology.
[484] H. Tajiri,et al. Improved immunogenicity of fusions between ethanol-treated cancer cells and dendritic cells exposed to dual TLR stimulation , 2013, Oncoimmunology.
[485] L. Zitvogel,et al. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. , 2013, Immunity.
[486] L. Zitvogel,et al. Dendritic cell-derived exosomes for cancer immunotherapy: what's next? , 2010, Cancer research.
[487] Angus G. Dalgleish,et al. The evolution of thalidomide and its IMiD derivatives as anticancer agents , 2004, Nature Reviews Cancer.
[488] M. Saleh. The machinery of Nod‐like receptors: refining the paths to immunity and cell death , 2011, Immunological reviews.
[489] J. Foloppe,et al. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus , 2008, Gene Therapy.
[490] T. D. de Gruijl,et al. IL-21 in cancer immunotherapy , 2013, Oncoimmunology.
[491] Vincent W. Li,et al. Cancer prevention by targeting angiogenesis , 2012, Nature Reviews Clinical Oncology.
[492] O. Gardner,et al. A Dose-Escalation Study of Recombinant Human Interleukin-18 in Combination With Rituximab in Patients With Non-Hodgkin Lymphoma , 2013, Journal of immunotherapy.
[493] Jinlong Li,et al. Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma , 2006, Cancer biology & therapy.
[494] L. Galluzzi. New immunotherapeutic paradigms for castration-resistant prostate cancer , 2013, Oncoimmunology.
[495] Wei Chen,et al. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. , 1998, Journal of immunology.
[496] Andrew E. Parker,et al. Targeting Toll-like receptors: emerging therapeutics? , 2010, Nature Reviews Drug Discovery.
[497] P. Darcy,et al. Gene-engineered T cells for cancer therapy , 2013, Nature Reviews Cancer.
[498] E. Lugli,et al. Inhibiting the inhibitors , 2013, Oncoimmunology.
[499] K. Sugamura,et al. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40 , 2004, Nature Reviews Immunology.
[500] M. Delorenzi,et al. Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy , 2014, Nature Medicine.
[501] J. Harden,et al. Chemoimmunotherapy as long-term maintenance therapy for cancer , 2012, Oncoimmunology.
[502] M. Boes,et al. Antitumor immune responses mediated by dendritic cells , 2013, Oncoimmunology.
[503] J. Kirkwood,et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. , 2014, JAMA.
[504] J. Mulé,et al. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[505] A. Bagg,et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.
[506] H. Ueno,et al. The expanding family of dendritic cell subsets , 2010, Nature Biotechnology.
[507] L. Zitvogel,et al. Trial Watch—Oncolytic viruses and cancer therapy , 2016, Oncoimmunology.
[508] T. Curiel,et al. High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN , 2005, Cancer biology & therapy.
[509] Maxim N. Artyomov,et al. Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens , 2014, Nature.
[510] G. Prendergast,et al. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer , 2014, Cancer Immunology, Immunotherapy.
[511] S. Armeanu-Ebinger,et al. Targeting EpCAM (CD326) for immunotherapy in hepatoblastoma , 2013, Oncoimmunology.
[512] B. Baban,et al. Cutting Edge: Induced Indoleamine 2,3 Dioxygenase Expression in Dendritic Cell Subsets Suppresses T Cell Clonal Expansion1 , 2003, The Journal of Immunology.
[513] H. Fujii,et al. Cetuximab induce antibody‐dependent cellular cytotoxicity against EGFR‐expressing esophageal squamous cell carcinoma , 2007, International journal of cancer.
[514] S. Lohse,et al. EGFR expression levels affect the mode of action of EGFR-targeting monoclonal antibodies , 2013, Oncoimmunology.
[515] D. Bigner,et al. Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody , 2013, Oncoimmunology.
[516] Steven M. Pincus,et al. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period. , 1995, Clinical Cancer Research.
[517] Richard E. T. Smith,et al. From the analyst's couch: TLR-targeted therapeutics. , 2005, Nature reviews. Drug discovery.
[518] A. Ullrich,et al. Paul Ehrlich's magic bullet concept: 100 years of progress , 2008, Nature Reviews Cancer.
[519] R. Jenq,et al. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer , 2010, Nature Reviews Cancer.
[520] E. Vizi,et al. CD39 and CD73 in immunity and inflammation. , 2013, Trends in molecular medicine.